<DOC>
	<DOCNO>NCT00680316</DOCNO>
	<brief_summary>This Phase IV , multicenter , randomize , double-blind , placebo-controlled trial design evaluate effect Pulmozyme pulmonary function , health-related quality life ( HRQOL ) , respiratory symptom 3- 5-year-old child cystic fibrosis ( CF ) . Approximately 40 patient plan enrol study . However , 3 patient eligible random allocation receive treatment : 1 patient Pulmozyme group 2 patient placebo group . All 3 patient complete study assessment usable pulmonary function test ( PFT ) data .</brief_summary>
	<brief_title>A Study PulmozymeÂ® ( Dornase Alpha ) 3- 5-Year-Old Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Signed Informed Consent Form Aged 35 year Diagnosis cystic fibrosis Children take schedule inhaled Pulmozyme hypertonic saline within 56 day prior Visit 1 Pulmozyme 28 day Visit 1 Involvement clinical intervention trial within 4 week prior Visit 1 Use investigational drug device within 28 day prior Visit 1 Any condition might increase risk participation patient judgement investigator</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Pulmozyme</keyword>
	<keyword>CF</keyword>
</DOC>